Herpes zoster ophthalmicus after COVID-19 vaccine booster in healthy younger adult: a case report

1Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.
Get full text

Abstract

There were growing reports of herpes zoster reactivation after the coronavirus disease 2019 (COVID-19) vaccination, including a more severe form, herpes zoster ophthalmicus (HZO). A 35-year-old male presented HZO in his left V1 dermatome 10 days after his COVID-19 vaccine booster with Moderna (messenger RNA-1273). He had no history of chronic disease, immuno-compromised, autoimmune, malignancy, or long-term immunosuppressive drug use. The rash improved without any further complications after being treated with oral valacyclovir for 7 days. This was a unique case of HZO after the COVID-19 vaccine in a booster setting in healthy younger adults. The association of herpes zoster after a COVID vaccine remained inconclu-sive and potentially coincidental, especially without the known risk factor. However, we would like to add a report to increase awareness among physicians and the general population, for early recognition and treatment with an antiviral.

Cite

CITATION STYLE

APA

Awaly, Z. W. N. (2023). Herpes zoster ophthalmicus after COVID-19 vaccine booster in healthy younger adult: a case report. Clinical and Experimental Vaccine Research, 12(1), 82–84. https://doi.org/10.7774/cevr.2023.12.1.82

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free